Pfizer (NYSE:PFE) dropped by -1.56 or -0.55 points during the last session to $34.74 per share. One of the highlights of the day was the net money flow figure, which stood at $65.36 million even as the stock accepted $203.77 million in upticks but rejected $138.42 million in downticks. The up/down ratio for the last observation was a 1.47. The 1-week percentage change for the stock price is registered at 0.14%.A block transaction occurred with $109.69 million in upticks and $50.89 million in downticks while the up/down ratio was calculated to be 2.16. The stock witnessed a net inflow of $58.8 million at the end of the block trade.
Currently the company Insiders own 0.07% of Pfizer shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.54% . Institutional Investors own 75.07% of Pfizer shares. During last six month period, the net percent change held by insiders has seen a change of -18.54%. On the companys insider trading activities, Damelio Frank A, officer (Executive Vice President) of Pfizer Inc, unloaded 100,000 shares at an average price of $34.49 on May 26, 2016. The total amount of the transaction was worth $3,449,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Pfizer (NYSE:PFE) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.55 points or 1.56% at $34.74 with 29,692,587 shares getting traded. Post opening the session at $35.02, the shares hit an intraday low of $34.7 and an intraday high of $35.15 and the price was in this range throughout the day. The company has a market cap of $210,693 million and the number of outstanding shares have been calculated to be 6,064,849,400 shares. The 52-week high of Pfizer (NYSE:PFE) is $36.46 and the 52-week low is $28.25.
Many analysts have stated their opinion on the company shares. Berenberg initiates coverage on Pfizer (NYSE:PFE).The analysts at the brokerage house have a current rating of Hold on the shares. In a recent information released to the investors, Berenberg announces the price target of $38 per share. The rating by the firm was issued on May 12, 2016.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.